Evidence map›Paper›PMID 29795057›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Identification of Biological Targets of Therapeutic Intervention for Hepatocellular Carcinoma by Integrated Bioinformatical Analysis.

Wei Qi Hu, Wei Wang, Di Long Fang, Xue Feng Yin

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Gene targets with therapeutic potential in hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Current Advances inFrontiers in pharmacology · 2021
    Review
  8. Article
  9. Identification of Potentially Therapeutic Target Genes of Hepatocellular Carcinoma.International journal of environmental research and public health · 2020
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wei Qi HuDepartment of General Surgery, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China (mainland).
Wei WangDepartment of General Surgery, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China (mainland).
Di Long FangDepartment of General Surgery, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China (mainland).
Xue Feng YinDepartment of General Surgery, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China (mainland).
Hangzhou Red Cross Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND We screened the potential molecular targets and investigated the molecular mechanisms of hepatocellular carcinoma (HCC). MATERIAL AND METHODS Microarray data of GSE47786, including the 40 μM berberine-treated HepG2 human hepatoma cell line and 0.08% DMSO-treated as control cells samples, was downloaded from the GEO database. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were performed; the protein-protein interaction (PPI) networks were constructed using STRING database and Cytoscape; the genetic alteration, neighboring genes networks, and survival analysis of hub genes were explored by cBio portal; and the expression of mRNA level of hub genes was obtained from the Oncomine databases. RESULTS A total of 56 upregulated and 8 downregulated DEGs were identified. The GO analysis results were significantly enriched in cell-cycle arrest, regulation of transcription, DNA-dependent, protein amino acid phosphorylation, cell cycle, and apoptosis. The KEGG pathway analysis showed that DEGs were enriched in MAPK signaling pathway, ErbB signaling pathway, and p53 signaling pathway. JUN, EGR1, MYC, and CDKN1A were identified as hub genes in PPI networks. The genetic alteration of hub genes was mainly concentrated in amplification. TP53, NDRG1, and MAPK15 were found in neighboring genes networks. Altered genes had worse overall survival and disease-free survival than unaltered genes. The expressions of EGR1, MYC, and CDKN1A were significantly increased, but expression of JUN was not, in the Roessler Liver datasets. CONCLUSIONS We found that JUN, EGR1, MYC, and CDKN1A might be used as diagnostic and therapeutic molecular biomarkers and broaden our understanding of the molecular mechanisms of HCC.

Indexed as

Molecular Targeted TherapyBerberineCarcinoma, HepatocellularCell Line, TumorComputational BiologyDatabases, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticGene OntologyGenes, NeoplasmHep G2 CellsHumansLiver NeoplasmsProtein Interaction MapsSurvival AnalysisBerberine

Identifiers

PMID29795057
PMCPMC5996840
OpenAlexW2803104118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.